Air Pollution and COPD Exacerbation

Impact of Air Pollution on Chronic Obstructive Pulmonary Disease (COPD) Exacerbation in Haut de France. BePoPi Project.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03904875

Acronym

BePoPi

Enrollment

120

Registered

2019-04-05

Start date

2020-01-01

Completion date

2023-09-12

Last updated

2023-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease, Pollution; Exposure

Keywords

pollution, Chronic Obstructive Pulmonary Disease, ultrathin particles

Brief summary

There is an excess of hospitalization rates for acute exacerbation of COPD in Picardy compared to the national data. A first study realized in Picardy has shown a link between air quality and COPD. Nevertheless, the particles type is unknown and according to it, impact on COPD could be different. The investigator goal is to find a correlation between acute exacerbation of COPD consultation rate and daily ultra thin particles in Haut de France. The investigators will correlate the particles composition with daily acute exacerbation of COPD rate. All COPD patients with a diagnosis of acute exacerbation in emergency room in University Hospital of Amiens-Picardie and Lille, and Clinique de l'Europe between 01/01/2020 and 31/12/2020 will be included. For each patient, home and work address will be collected. The duration of 1 year was chosen to take into account seasonal variations. In parallel, a daily report of the rate of ozone, particles (PM2.5 and PM10), dioxide nitrogen but also odours and pollens will be done by ATMO Haut de France.

Interventions

OTHERcollection of data about each acute exacerbation of COPD

COPD is chronic obstructive pulmonary disease. Data collected are need of hospitalisation, final diagnosis, home address, work address and air quality data.

Study design

Observational model

ECOLOGIC_OR_COMMUNITY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* COPD patients with a diagnosis of acute exacerbation of COPD in the emergency room of Amiens and Lille centers * Adults * Patients able to express consent * signed written informed consent form * covered by national health insurance

Exclusion criteria

* patients non covered by national health insurance * patients not able to express consent * minors

Design outcomes

Primary

Measure	Time frame	Description
daily rate of COPD exacerbation consultation in the emergency room of the 3 centers	every day during 12 months	daily rate of COPD exacerbation consultation in the emergency room of the 3 centers
ultrathin particles quantity in the air	every day during 12 months	ultrathin particles quantity will be determined by the air of Haut de France by the company ATMO Haut de France.

Secondary

Measure	Time frame	Description
chemical composition ultrathin particles	every day during 12 months	chemical composition ultrathin particles will be determined by the air of Haut de France by the company ATMO Haut de France.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026